Triple Negative Breast Cancer: Molecular Subtype-Specific Immune Landscapes with Therapeutic Implications
Cancers · 31.05.2024 · 16 (11) · 2094
DOI: 10.3390/cancers16112094 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 31.05.2024. Verfasst von Antonia Syrnioti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Triple Negative Breast Cancer (TNBC) is characterized by distinct molecular subtypes with unique biological and clinical features. This systematic review aimed to identify articles examining the differences in the tumor immune microenvironment (TIME) across different TNBC molecular subtypes. Six studies meeting inclusion criteria were analyzed, utilizing gene expression profiling and bioinformatic analyses to classify TNBC samples into molecular subtypes, as well as immunohistochemistry and cell deconvolution methods to characterize the TIME. Results revealed significant heterogeneity in immune cell composition among TNBC subtypes, with the immunomodulatory (IM) subtype demonstrating robust immune infiltration, composed mainly of adaptive immune cells along with an increased density of CTLA-4+ and PD-1+ TILs, high PD-L1 tumor cell expression, and upregulation of FOXP3+ Tregs. A more immunosuppressive TIME with a predominance of innate immune cells and lower levels of tumor-infiltrating lymphocytes (TILs) was observed in luminal androgen receptor (LAR) tumors. In mesenchymal stem-like (MSL) tumors, the TIME was mainly composed of innate immune cells, with a high number of M2 tumor-associated macrophages (TAMs), while the BL and M tumors displayed poor adaptive and innate immune responses, indicating an “immune-cold” phenotype. Differential activation of signaling pathways, genomic diversity, and metabolic reprogramming were identified as contributors to TIME heterogeneity. Understanding this interplay is crucial for tailoring therapeutic strategies, especially regarding immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- 2nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Department of Breast Surgery, New York Presbyterian-Weill Cornell Medicine, New York, NY 10065, USA.
- MSc Program in Gynaecologic Oncology and Breast Oncology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Laboratory of Histology-Embryology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
ORCID-Profile: Antonia Syrnioti, Stamatios Petousis, Theodora Papamitsou, Konstantinos Dinas, Triantafyllia Koletsa
Zitieren
APA
Syrnioti, A., Petousis, S., Newman, L. A., Margioula-Siarkou, C., Papamitsou, T., Dinas, K., & Koletsa, T. (2024). Triple Negative Breast Cancer: Molecular Subtype-Specific Immune Landscapes with Therapeutic Implications. Cancers, 16(11), 2094. https://doi.org/10.3390/cancers16112094
Vancouver
Syrnioti A, Petousis S, Newman LA, Margioula-Siarkou C, Papamitsou T, Dinas K, et al. Triple Negative Breast Cancer: Molecular Subtype-Specific Immune Landscapes with Therapeutic Implications. Cancers. 2024;16(11):2094. doi:10.3390/cancers16112094
BibTeX
@article{Syrnioti2024,
author = {Syrnioti, Antonia and Petousis, Stamatios and Newman, Lisa A and Margioula-Siarkou, Chrysoula and Papamitsou, Theodora and Dinas, Konstantinos and Koletsa, Triantafyllia},
title = {Triple Negative Breast Cancer: Molecular Subtype-Specific Immune Landscapes with Therapeutic Implications},
journal = {Cancers},
year = {2024},
volume = {16},
number = {11},
pages = {2094},
doi = {10.3390/cancers16112094}
}
EUVIMED